Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Solbach

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2012
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapyC Denkert, S Loibl, R Kronenwett, et al.
ESMO Open|November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)T Link, M Reinisch, M Just, et al.
Breast Cancer Research and Treatment|August 20, 2017
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trialA G J van Rossum, P C Schouten, K E Weber, et al.
ESMO Open|April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)P Meyer-Wilmes, J Huober, M Untch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Genomic characterisation of hormone receptor-positive breast cancer arising in very young womenS J Luen, G Viale, S Nik-Zainal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2012
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapyC Denkert, S Loibl, R Kronenwett, et al.
ESMO Open|November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)T Link, M Reinisch, M Just, et al.
Breast Cancer Research and Treatment|August 20, 2017
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trialA G J van Rossum, P C Schouten, K E Weber, et al.
ESMO Open|April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)P Meyer-Wilmes, J Huober, M Untch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Genomic characterisation of hormone receptor-positive breast cancer arising in very young womenS J Luen, G Viale, S Nik-Zainal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 5